Melioidosis: Advances in diagnosis and treatment

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 554-559

  Cheng, Allen C ^a,b,c  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

Author keywords

antibacterial agents; Burkholderia pseudomallei; melioidosis; serological tests; severe sepsis

Indexed keywords

ACTIVATED PROTEIN C; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFOPERAZONE; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; DROTRECOGIN; FOLIC ACID; IMIPENEM; IMMUNOMODULATING AGENT; MEROPENEM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SULBACTAM;

ADJUVANT THERAPY; BACTERIAL ARTHRITIS; BACTERIUM CULTURE; CLINICAL TRIAL; COMMUNITY ACQUIRED SEPSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; ENZYME IMMUNOASSAY; GRAM STAINING; HEMAGGLUTINATION TEST; HUMAN; INDIRECT HEMAGGLUTINATION ASSAY; INFECTION RISK; MELIOIDOSIS; NUCLEIC ACID ANALYSIS; NUCLEOTIDE SEQUENCE; OSTEOMYELITIS; PATIENT CARE; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEPSIS; SEROLOGY; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; CEFTAZIDIME; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; HUMANS; MELIOIDOSIS; SENSITIVITY AND SPECIFICITY; SEPSIS; THIENAMYCINS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 78349309039     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833fb88c     Document Type: Review

References (48)

1. White NJ. Melioidosis. Lancet. 2003; 361: 1715-1722.
2. Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005; 18:383-416.
3. Limmathurotsakul D, Wongratanacheewin S, Teerawattanasook N, et al. Increasing incidence of human melioidosis in northeast Thailand. Am J Trop Med Hyg 2010; 82:1113-1117.
4. Walsh AL, Wuthiekanun V. The laboratory diagnosis of melioidosis. Br J Biomed Sci 1996; 53:249-253.
5. Ashdown LR. An improved screening technique for isolation of Pseudomo-nas pseudomallei from clinical specimens. Pathology 1979; 11:293-297.
6. Peacock SJ, Chieng G, Cheng AC, et al. Comparison of Ashdown's medium, Burkholderia cepacia medium, and Burkholderia pseudomallei selective agar for clinical isolation of Burkholderia pseudomallei. J Clin Microbiol 2005; 43:5359-5361.
7. Wuthiekanun V, Desakorn V, Wongsuvan G, et al. Rapid immunofluorescence microscopy for diagnosis of melioidosis. Clin Diagn Lab Immunol. 2005; 12: 555-556.
8. Cheng AC, Wuthiekanun V, Limmathurotsakul D, et al. Intensity of exposure and incidence of melioidosis in Thai children. Trans R Soc Trop Med Hyg 2008; 102 (Suppl 1):S37-S39.
9. Wuthiekanun V, Chierakul W, Langa S, et al. Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. Am J Trop Med Hyg 2006; 74:1074-1075.
10. Ashdown LR, Guard RW. The prevalence of human melioidosis in northern Queensland. Am J Trop Med Hyg 1984; 33:474-478.
11. Cheng AC, O'Brien M, Freeman K, et al. Indirect hemagglutination assay in patients with melioidosis in northern Australia. Am J Trop Med Hyg 2006; 74:330-334.
12. Cheng AC, Peacock SJ, Limmathurotsakul D, et al. Prospective evaluation of a rapid immunochromogenic cassette test for the diagnosis of melioidosis in northeast Thailand. Trans R Soc Trop Med Hyg 2006; 100: 64-67.
13. O'Brien M, Freeman K, Lum G, et al. Further evaluation of a rapid diagnostic test for melioidosis in an area of endemicity. J Clin Microbiol 2004; 42:2239-2240.
14. Meumann EM, Novak RT, Gal D, et al. Clinical evaluation of a type III secretion system real-time PCR assay for diagnosing melioidosis. J Clin Microbiol 2006; 44:3028-3030.
15. Chantratita N, Meumann E, Thanwisai A, et al. Loop-mediated isothermal amplification method targeting the TTS1 gene cluster for the detection of Burkholderia pseudomallei and diagnosis of melioidosis. J Clin Microbiol 2008; 46:568-573.
16. White NJ, Dance DA, Chaowagul W, et al. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; 2:697-701.
17. Chaowagul W, ChierakulW, Simpson AJ, et al. Open-label randomized trial of oral trimethoprim-sulfamethoxazole, doxycycline, and chloramphenicol compared with trimethoprim-sulfamethoxazole and doxycycline for maintenance therapy of melioidosis. Antimicrob Agents Chemother 2005; 49:4020-4025.
18. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31:981-986.
19. Sookpranee M, Boonma P, Susaengrat W, et al. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphe-nicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992; 36:158-162.
20. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19:846-853.
21. Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999; 29:381-387.
22. Thamprajamchit S, Chetchotisakd P, Thinkhamrop B. Cefoperazone/sulbac-tam + co-trimoxazole vs ceftazidime + co-trimoxazole in the treatment of severe melioidosis: a randomized, double-blind, controlled study. J Med Assoc Thai 1998; 81:265-271.
23. Chetchotisakd P, Porramatikul S, Mootsikapun P, et al. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin Infect Dis 2001; 33:29-34.
24. Chierakul W, Anunnatsiri S, Short JM, et al. Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. Clin Infect Dis 2005; 41:1105-1113.
25. Cheng AC, Limmathurotsakul D, Chierakul W, et al. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin Infect Dis 2007; 45:308-314.
26. Smith MD, Wuthiekanun V, Walsh AL, White NJ. In-vitro activity of carbape-nem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. J Antimicrob Chemother 1996; 37:611-615.
27. Cheng AC, Fisher DA, Anstey NM, et al. Outcomes of patients with melioidosis treated with meropenem. Antimicrob Agents Chemother 2004; 48:1763-1765.
28. Rajchanuvong A, Chaowagul W, Suputtamongkol Y, et al. A prospective comparison of co-amoxiclav and the combination of chloramphenicol, dox-ycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1995; 89:546-549.
29. Suputtamongkol Y, Dance DA, Chaowagul W, et al. Amoxycillin-clavulanic acid treatment of melioidosis. Trans R Soc Trop Med Hyg 1991; 85:672-675.
30. Cheng AC, McBryde ES, Wuthiekanun V, et al. Dosing regimens of cotrimox-azole (trimethoprim-sulfamethoxazole) for melioidosis. Antimicrob Agents Chemother 2009; 53:4193-4199.
31. Chaowagul W, Simpson AJ, Suputtamongkol Y, et al. A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. Clin Infect Dis 1999; 29:375-380.
32. Chetchotisakd P, Chaowagul W, Mootsikapun P, et al. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am J Trop Med Hyg 2001; 64 (1-2):24-27.
33. Chaowagul W, Suputtamongkol Y, Smith MD, White NJ. Oral fluoroquino-lones in the maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1997; 91:599-601.
34. Tan CK, Chan KS, Yu WL, et al. Successful treatment of life-threatening melioidosis with activated protein C and meropenem. J Microbiol Immunol Infect 2007; 40:83-87.
35. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
36. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358:125-139.
37. Cheng AC, Stephens DP, Anstey NM, Currie BJ. Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. Clin Infect Dis 2004; 38:32-37.
38. Wiersinga WJ, Kager LM, Hovius JW, et al. Urokinase receptor is necessary for bacterial defense against pneumonia-derived septic melioidosis by facilitating phagocytosis. J Immunol 2010; 184:3079-3086.
39. Wiersinga WJ, Wieland CW, Dessing MC, et al. Toll-like receptor 2 impairs host defense in Gramnegative sepsis caused by Burkholderia pseudomallei (melioidosis). PLoS Med 2007; 4:e248.
40. Wiersinga WJ, van't Veer C, van den Pangaart PS, et al. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gramnegative sepsis (melioidosis). Crit Care Med 2009; 37:569-576.
41. Cheng AC, West TE, Limmathurotsakul D, Peacock SJ. Strategies to reduce mortality from bacterial sepsis in adults in developing countries. PLoS Med 2008; 5:e175.
42. Becker JU, Theodosis C, Jacob ST, et al. Surviving sepsis in low-income and middle-income countries: new directions for care and research. Lancet Infect Dis 2009; 9:577-582.
43. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008. Crit Care Med 2008; 36:296-327.
44. Eichacker PQ, Natanson C, Danner RL. Surviving sepsis: practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 2006; 355:1640-1642.
45. Ferrer R, Artigas A, Levy MM, et al. Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain. JAMA 2008; 299:2294-2303.
46. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36:222-231.
47. Jacob ST, Moore CC, Banura P, et al. Severe sepsis in two Ugandan hospitals: a prospective observational study of management and outcomes in a predominantly HIV-1 infected population. PLoS One 2009; 4:e7782.
48. Phetsouvanh R, Phongmany S, Newton P, et al. Melioidosis and Pandora's box in the Lao People's Democratic Republic. Clin Infect Dis 2001; 32:653-654.